Lifetime of transplanted kidneys can be prolonged

Lifetime of transplanted kidneys can be prolonged

The drug Belatacept, which the Medical University of Vienna – represented by Ferdinand Mühlbacher, Head of the University Department of Surgery and the immunologist Thomas Wekerle – was greatly involved in the development of, has been approved for almost two years now. Belatacept is a co-stimulation blocker that suppresses the immune response in kidney transplants and has few side effects. "Plus there are indications that the drug can also help significantly prolong the lifetime of the transplanted organ," says Wekerle.

There is no final data available yet on the lifetime of transplanted kidneys and subsequent therapy with Belatacept, however estimates predict a prolongation of several years compared to the current treatment regime based on the conventional immunosuppressants known as calcineurin inhibitors.

The new therapy also has another advantage compared to calcineurin inhibitors: it has no non-specific side effects. For almost 30 years, have been used for the lifelong suppression of adverse reactions of the immune system to . These drugs have been associated with possible adverse side effects such as , disturbances of fat metabolism or diabetes.

At the same time, Belatacept is much easier to administer as a medication: every four weeks, the patient is given an infusion that takes around 30 minutes. With , the patients have to take tablets every day. At the present time, Belatacept treatment is not funded by health insurance funds. The costs for patients treated with this drug at the Vienna General Hospital / MedUni Vienna, however, are paid for by the hospital and/or university. Says Wekerle: "Of course, in an ideal world the costs would be borne by the social security funds."

A vision of the future: bone marrow transplant instead of medication

Current research being carried out by MedUni Vienna scientists, however, is already going one step further. In future, will no longer be required at all, being replaced by a from the donor. This prevents any defence reaction against the "foreign" organ.

This is however still associated with adverse side effects: recipients must first be irradiated and be given synthetic substances (cytostatics) to inhibit cell growth or cell division. This treatment is associated with nausea and a reduction in white and/or red blood cells. "If we are able to reduce this toxicity or eliminate it altogether, it would be revolutionary," says Wekerle. "If we are able to get the foreign bone marrow to graft, the recipient will not recognise the donor organ as foreign. There will be no immune response. Instead, the patient tolerates it." Initial pilot studies have shown that this method promises success.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

ALS Ice Bucket Challenge arrives in North Korea

17 hours ago

It's pretty hard to find a novel way to do the ALS Ice Bucket Challenge by now, but two-time Grammy-winning rapper Pras Michel, a founding member of the Fugees, has done it—getting his dousing in the center ...

Cold cash just keeps washing in from ALS challenge

Aug 28, 2014

In the couple of hours it took an official from the ALS Association to return a reporter's call for comment, the group's ubiquitous "ice bucket challenge" had brought in a few million more dollars.

Medtronic spends $350M on another European deal

Aug 27, 2014

U.S. medical device maker Medtronic is building stronger ties to Europe, a couple months after announcing a $42.9 billion acquisition that involves moving its main executive offices across the Atlantic, where it can get a ...

User comments